Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome

genetic polymorphisms and their possible impact on survival of patients with PDA. gene: C170T (rs52812045), TG1527del (rs3838646), A1626G (rs1058881) and A1056G (rs1058818). SNP combinations were: heterozygote for A1626G and WT for the rest of the alleles (14% of patients), heterozygote for C170T, A1626G, A1056G and WT for the rest (14% of patients), and heterozygote for C170T, A1056G and WT for the rest (10% of patients). All patients were APC WT. The first two groups were significantly younger at diagnosis than the third group. genes may play a role in pancreatic cancer development. Correlation with survival requires a larger cohort